Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2134–2142. doi: 10.1128/aac.38.9.2134

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.

R R Bowsher 1, J A Compton 1, J A Kirkwood 1, G D Place 1, C D Jones 1, T E Mabry 1, D L Hyslop 1, B L Hatcher 1, K A DeSante 1
PMCID: PMC284697  PMID: 7811032

Abstract

Fialuridine (FIAU) is a halogen-substituted analog of thymidine that was undergoing clinical investigation as a drug for the treatment of chronic hepatitis B viral infection. However, clinical trials of FIAU were terminated after adverse events occurred following chronic oral administration. Prior to the termination of clinical trials, a sensitive assay was needed for the measurement of FIAU because of the anticipated low dose administered to patients. We therefore undertook the development of a radioimmunoassay (RIA). A specific antiserum was raised in rabbits following immunization with a 5'-O-hemisuccinate analog of FIAU coupled to keyhole limpet hemocyanin. Radiolabeled FIAU was synthesized by a destannylation procedure by using sodium [125I]iodide. We developed a competitive-binding procedure and used precipitation with polyethylene glycol as the method for separating the bound and free forms of FIAU. The RIA is sensitive (0.2 ng/ml), specific (negligible interference from known metabolites and endogenous nucleosides), and reproducible (interassay coefficients of variation range from 5 to 19.7% for serum controls). We used the RIA to assess the pharmacokinetics of FIAU in healthy adult volunteers following administration of a single 5-mg oral dose. The sensitivity of the RIA permitted the detection of a prolonged elimination phase for FIAU in healthy volunteers and dogs, with mean elimination half-lives of 29.3 and 35.3 h, respectively. We conclude the RIA is a valid method for the quantification of FIAU in biological fluids.

Full text

PDF
2134

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin R. K., Trefts P. E., Hintz M., Connor J. D., Kagnoff M. F. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother. 1983 Nov;24(5):696–701. doi: 10.1128/aac.24.5.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bubnis W. A., Ofner C. M., 3rd The determination of epsilon-amino groups in soluble and poorly soluble proteinaceous materials by a spectrophotometric method using trinitrobenzenesulfonic acid. Anal Biochem. 1992 Nov 15;207(1):129–133. doi: 10.1016/0003-2697(92)90513-7. [DOI] [PubMed] [Google Scholar]
  3. Chard T. Ammonium sulfate and polyethylene glycol as reagents to separate antigen from antigen-antibody complexes. Methods Enzymol. 1980;70(A):280–291. doi: 10.1016/s0076-6879(80)70057-5. [DOI] [PubMed] [Google Scholar]
  4. Chou T. C., Feinberg A., Grant A. J., Vidal P., Reichman U., Watanabe K. A., Fox J. J., Philips F. S. Pharmacological disposition and metabolic fate of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mice and rats. Cancer Res. 1981 Sep;41(9 Pt 1):3336–3342. [PubMed] [Google Scholar]
  5. Cload P. A. A review of the pharmacokinetics of zidovudine in man. J Infect. 1989 Jan;18 (Suppl 1):15–21. doi: 10.1016/s0163-4453(89)80076-3. [DOI] [PubMed] [Google Scholar]
  6. Colacino J. M., Lopez C. Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents. Antimicrob Agents Chemother. 1983 Oct;24(4):505–508. doi: 10.1128/aac.24.4.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Colbert D. L., Eremin S. A., Landon J. The effect of fluorescein labels on the affinity of antisera to small haptens. J Immunol Methods. 1991 Jul 5;140(2):227–233. doi: 10.1016/0022-1759(91)90375-p. [DOI] [PubMed] [Google Scholar]
  8. Collins J. M., Unadkat J. D. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989 Jul;17(1):1–9. doi: 10.2165/00003088-198917010-00001. [DOI] [PubMed] [Google Scholar]
  9. Cox S., Rudén U., Nagy K., Albert J., Holmberg V., Sandström E., Wahren B. Serum levels and catabolism of 3'-azido-3'-deoxythymidine in vivo measured using a specific radioimmunoassay. J Virol Methods. 1990 Oct;30(1):89–98. doi: 10.1016/0166-0934(90)90046-i. [DOI] [PubMed] [Google Scholar]
  10. Drew W. L., Miner R., King D. Antiviral activity of FIAU (1-[2'deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-iodo-uridine) on strains of cytomegalovirus sensitive and resistant to ganciclovir. J Infect Dis. 1991 Jun;163(6):1388–1389. doi: 10.1093/infdis/163.6.1388. [DOI] [PubMed] [Google Scholar]
  11. Dudley R. A., Edwards P., Ekins R. P., Finney D. J., McKenzie I. G., Raab G. M., Rodbard D., Rodgers R. P. Guidelines for immunoassay data processing. Clin Chem. 1985 Aug;31(8):1264–1271. [PubMed] [Google Scholar]
  12. ERLANGER B. F., BOREK F., BEISER S. M., LIEBERMAN S. Steroid-protein conjugates. I. Preparation and characterization of conjugates of bovine serum albumin with testosterone and with cortisone. J Biol Chem. 1957 Oct;228(2):713–727. [PubMed] [Google Scholar]
  13. ERLANGER B. F., BOREK F., BEISER S. M., LIEBERMAN S. Steroid-protein conjugates. II. Preparation and characterization of conjugates of bovine serum albumin with progesterone, deoxycorticosterone, and estrone. J Biol Chem. 1959 May;234(5):1090–1094. [PubMed] [Google Scholar]
  14. Feinberg A., Leyland-Jones B., Fanucchi M. P., Hancock C., Fox J. J., Watanabe K. A., Vidal P. M., Williams L., Young C. W., Philips F. S. Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. Antimicrob Agents Chemother. 1985 May;27(5):733–738. doi: 10.1128/aac.27.5.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fourel I., Hantz O., Cova L., Allaudeen H. S., Trepo C. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. Antiviral Res. 1987 Nov;8(4):189–199. doi: 10.1016/0166-3542(87)90073-8. [DOI] [PubMed] [Google Scholar]
  16. Fourel I., Hantz O., Watanabe K. A., Jacquet C., Chomel B., Fox J. J., Trepo C. Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 1990 Mar;34(3):473–475. doi: 10.1128/aac.34.3.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fourel I., Li J., Hantz O., Jacquet C., Fox J. J., Trépo C. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol. 1992 Jun;37(2):122–126. doi: 10.1002/jmv.1890370209. [DOI] [PubMed] [Google Scholar]
  18. Földes O., Uherová P., Mayer V. Plasma levels of the anti-HIV drug 3'-azido-2',3'-dideoxythymidine (AZT): determination by RIA and HPLC. Acta Virol. 1993 Apr-Jun;37(2-3):156–164. [PubMed] [Google Scholar]
  19. Gish D. T., Kelly R. C., Camiener G. W., Wechter W. J. Nucleic acids. 11. Synthesis of 5'-esters of 1-beta-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity. J Med Chem. 1971 Dec;14(12):1159–1162. doi: 10.1021/jm00294a004. [DOI] [PubMed] [Google Scholar]
  20. Grant A. J., Feinberg A., Chou T. C., Watanabe K. A., Fox J. J., Philips F. S. Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol. 1982 Mar 15;31(6):1103–1108. doi: 10.1016/0006-2952(82)90349-5. [DOI] [PubMed] [Google Scholar]
  21. Hantz O., Allaudeen H. S., Ooka T., De Clercq E., Trepo C. Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res. 1984 Aug;4(4):187–199. doi: 10.1016/0166-3542(84)90017-2. [DOI] [PubMed] [Google Scholar]
  22. Langtry H. D., Campoli-Richards D. M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Apr;37(4):408–450. doi: 10.2165/00003495-198937040-00003. [DOI] [PubMed] [Google Scholar]
  23. Lopez C., Watanabe K. A., Fox J. J. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803–806. doi: 10.1128/aac.17.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Macilwain C. NIH, FDA seek lessons from hepatitis B drug trial deaths. Nature. 1993 Jul 22;364(6435):275–275. doi: 10.1038/364275d0. [DOI] [PubMed] [Google Scholar]
  25. Morse G. D., Portmore A., Olson J., Taylor C., Plank C., Reichman R. C. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1990 Mar;34(3):394–397. doi: 10.1128/aac.34.3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Morse G. D., Shelton M. J., O'Donnell A. M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet. 1993 Feb;24(2):101–123. doi: 10.2165/00003088-199324020-00002. [DOI] [PubMed] [Google Scholar]
  27. Okabayashi T., Mihara S., Repke D. B., Moffatt J. G. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1977 Feb;37(2):619–624. [PubMed] [Google Scholar]
  28. Okabayashi T., Mihara S., Repke D. B., Moffatt J. G. A radioimmunoassay for 1-beta-D-arabinofuranosyluracil with reference to cross-reactivity of 1-beta-D-arabinofuranosylcytosine with an antibody. Cancer Res. 1977 Sep;37(9):3132–3135. [PubMed] [Google Scholar]
  29. Okabayashi T., Moffatt J. G. Radioimmunoassay of 1-beta-D-arabinofuranosylcytosine. Methods Enzymol. 1982;84:470–483. doi: 10.1016/0076-6879(82)84035-4. [DOI] [PubMed] [Google Scholar]
  30. Pauillac S., Halmos T., Labrousse H., Antonakis K., Avrameas S. Production of highly specific monoclonal antibodies to monensin and development of a microELISA to detect this antibiotic. J Immunol Methods. 1993 Sep 15;164(2):165–173. doi: 10.1016/0022-1759(93)90309-u. [DOI] [PubMed] [Google Scholar]
  31. Philips F. S., Feinberg A., Chou T. C., Vidal P. M., Su T. L., Watanabe K. A., Fox J. J. Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-beta-D- arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5- iodocytosine. Cancer Res. 1983 Aug;43(8):3619–3627. [PubMed] [Google Scholar]
  32. Quinn R. P., Orban B., Tadepalli S. Radioimmunoassay for Retrovir, an anti-human immunodeficiency virus drug. J Immunoassay. 1989;10(2-3):177–189. doi: 10.1080/01971528908053235. [DOI] [PubMed] [Google Scholar]
  33. Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
  34. Rodbard D. Statistical estimation of the minimal detectable concentration ("sensitivity") for radioligand assays. Anal Biochem. 1978 Oct 1;90(1):1–12. doi: 10.1016/0003-2697(78)90002-7. [DOI] [PubMed] [Google Scholar]
  35. Sato T., Morozumi M., Kodama K., Kuninaka A., Yoshino H. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma. Cancer Treat Rep. 1984 Nov;68(11):1357–1366. [PubMed] [Google Scholar]
  36. Schreiber R., Raso V. Radioimmunoassay for the detection and quantitation of 5-fluorodexoyuridine. Cancer Res. 1978 Jul;38(7):1889–1892. [PubMed] [Google Scholar]
  37. Shimada N., Ueda T., Yokoshima T., Oh-Ishi J., Oh-oka T. A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine. Cancer Lett. 1984 Sep;24(2):173–178. doi: 10.1016/0304-3835(84)90133-2. [DOI] [PubMed] [Google Scholar]
  38. Snyder S. L., Sobocinski P. Z. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal Biochem. 1975 Mar;64(1):284–288. doi: 10.1016/0003-2697(75)90431-5. [DOI] [PubMed] [Google Scholar]
  39. Staschke K. A., Colacino J. M., Mabry T. E., Jones C. D. The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994 Jan;23(1):45–61. doi: 10.1016/0166-3542(94)90032-9. [DOI] [PubMed] [Google Scholar]
  40. Sterzycki R. Z., Ghazzouli I., Brankovan V., Martin J. C., Mansuri M. M. Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides. J Med Chem. 1990 Aug;33(8):2150–2157. doi: 10.1021/jm00170a017. [DOI] [PubMed] [Google Scholar]
  41. Stretcher B. N. State-of-the-art of zidovudine monitoring. J Clin Lab Anal. 1991;5(1):60–68. doi: 10.1002/jcla.1860050112. [DOI] [PubMed] [Google Scholar]
  42. Vallejo R. P., Bogus E. R., Mumma R. O. Effects of hapten structure and bridging groups on antisera specificity in parathion immunoassay development. J Agric Food Chem. 1982 May-Jun;30(3):572–580. doi: 10.1021/jf00111a040. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES